Clinical trial
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With…
NCT00144781 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00144781 |
|---|---|
| Title | A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease |
| Official title | A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | BioMarin/Genzyme LLC Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome |
| Intervention type | Biological |
| Interventions | Aldurazyme (Recombinant Human Alpha-L-Iduronidase) |
| Enrollment | 34 |
| Start date | Dec 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Brazil, Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: